High levels of E2F2 and elevated activity of the PI3K/AKT signaling pathway have been observed in DLBCL, while the latter has been associated with poor outcome of DLBCL patients, as well. The gene discussed is E2F2; the disease is diffuse large B-cell lymphoma.